NOVO.B.DK

232.05

+0.69%↑

GMAB.DK

1,712

+1.15%↑

HLUNB.DK

40.04

+2.25%↑

ZEAL.DK

297.8

+2.37%↑

AMBUB.DK

68.1

+0.52%↑

NOVO.B.DK

232.05

+0.69%↑

GMAB.DK

1,712

+1.15%↑

HLUNB.DK

40.04

+2.25%↑

ZEAL.DK

297.8

+2.37%↑

AMBUB.DK

68.1

+0.52%↑

NOVO.B.DK

232.05

+0.69%↑

GMAB.DK

1,712

+1.15%↑

HLUNB.DK

40.04

+2.25%↑

ZEAL.DK

297.8

+2.37%↑

AMBUB.DK

68.1

+0.52%↑

NOVO.B.DK

232.05

+0.69%↑

GMAB.DK

1,712

+1.15%↑

HLUNB.DK

40.04

+2.25%↑

ZEAL.DK

297.8

+2.37%↑

AMBUB.DK

68.1

+0.52%↑

NOVO.B.DK

232.05

+0.69%↑

GMAB.DK

1,712

+1.15%↑

HLUNB.DK

40.04

+2.25%↑

ZEAL.DK

297.8

+2.37%↑

AMBUB.DK

68.1

+0.52%↑

Search

Coloplast A-S (Class B)

Fechado

437.1 0.14

Visão Geral

Variação de preço das ações

24h

Atual

Mín

436.7

Máximo

443.6

Indicadores-chave

By Trading Economics

Rendimento

522M

1.4B

Vendas

83M

7B

P/E

Médio do Setor

24.382

57.05

EPS

6.32

Rendimento de Dividendos

5.47

Margem de lucro

19.835

Funcionários

16,983

EBITDA

309M

2.3B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+11.86% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

5.47%

2.52%

Próximos Ganhos

12 de mai. de 2026

Próxima data de dividendos

20 de mai. de 2026

Próxima data de ex-dividendo

18 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-21B

97B

Abertura anterior

436.96

Fecho anterior

437.1

Coloplast A-S (Class B) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de mar. de 2026, 23:15 UTC

Notícias Principais

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

30 de mar. de 2026, 22:36 UTC

Notícias Principais

Australian Government Rules Out Boots on the Ground in the Middle East

30 de mar. de 2026, 22:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

30 de mar. de 2026, 21:00 UTC

Ganhos

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

30 de mar. de 2026, 20:15 UTC

Notícias Principais

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

30 de mar. de 2026, 23:40 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 de mar. de 2026, 23:40 UTC

Conversa de Mercado

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

30 de mar. de 2026, 23:36 UTC

Conversa de Mercado

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

30 de mar. de 2026, 23:12 UTC

Conversa de Mercado

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

30 de mar. de 2026, 22:49 UTC

Conversa de Mercado

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

30 de mar. de 2026, 22:44 UTC

Conversa de Mercado

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

30 de mar. de 2026, 22:43 UTC

Conversa de Mercado

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

30 de mar. de 2026, 22:42 UTC

Conversa de Mercado

South32 Should Go for Growth, Says New Bull -- Market Talk

30 de mar. de 2026, 22:18 UTC

Conversa de Mercado

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

30 de mar. de 2026, 22:05 UTC

Conversa de Mercado

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

30 de mar. de 2026, 21:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life Financial Agrees to Buy Bell Partners for $350M

30 de mar. de 2026, 21:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

30 de mar. de 2026, 21:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

30 de mar. de 2026, 21:36 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

30 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

30 de mar. de 2026, 21:25 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 de mar. de 2026, 21:25 UTC

Conversa de Mercado

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

30 de mar. de 2026, 21:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

30 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

30 de mar. de 2026, 20:09 UTC

Ganhos

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

30 de mar. de 2026, 20:00 UTC

Notícias Principais

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Comparação entre Pares

Variação de preço

Coloplast A-S (Class B) Previsão

Preço-alvo

By TipRanks

11.86% parte superior

Previsão para 12 meses

Média 901.38 DKK  11.86%

Máximo 1,056 DKK

Mínimo 720 DKK

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Coloplast A-S (Class B) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

8 ratings

2

Comprar

4

Manter

2

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat